ERBB2 and breast cancer: For this purpose, we considered breast cancers, where amplifications of ERBB2 (Chromosome 17), CCND1 (Chromosome 11) and MYC (Chromosome 8) oncogenes are frequently observed (∼15%, 11% and 38%, respectively in the TCGA cohort).